Avadel Pharmaceuticals announced that it has achieved its patient enrollment target of 205 patients in the REST-ON Phase 3 clinical trial for FT218, an investigational, once-nightly formulation of sodium oxybate for the treatment of excessive daytime sleepiness and cataplexy in patients with narcolepsy. Patients currently in the screening process will also be allowed to enroll in the study if they meet the eligibility criteria. The last patient’s last visit is expected to occur by the end of the first quarter of 2020, with topline data expected in the second quarter of 2020.

To read more about the study, go here.